US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...

The instances of ARIA were primarily seen in participants treated with AL002. “We, at Alector, recognize the importance of advancing therapeutics to treat Alzheimer’s disease and remain ...

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

Alector的产品管道中包括多种候选药物，例如AL001、AL002、AL003和AL101，正处于临床试验阶段。 在生物技术行业，创新是生死攸关的问题，而市场的敏感 ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Jeffrey Hung has given his Sell rating due to a combination of factors, primarily driven by the unfavorable ...

周二，Morgan Stanley调整了对Alector Inc. (NASDAQ:ALEC)股票的立场，将其评级从持平下调至减持。该公司还大幅下调了目标价格，将其从之前的10.00美元大幅下调至3.00美元。

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on ALEC stock, giving a Buy rating today.Don't Miss our Black ...